J&J pledges not to enforce TB patents in certain countries

03-10-2023

Muireann Bolger

J&J pledges not to enforce TB patents in certain countries

sundryphotography / Shutterstock.com

In a move welcomed by healthcare charities, Johnson & Johnson (J&J) has confirmed that it will not enforce patents it owns and controls for Sirturo (bedaquiline) in the treatment of multidrug-resistant tuberculosis (MDR-TB) in 134 low-and middle-income countries.


Johnson & Johnson, generic, treatment, bedaquiline,, tuberculosis, pharma, MDR-TB, litigation, multidrug-resistant, Sirturo, advocacy, patents

LSIPR